Dyadic International Inc (DYAI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Dyadic International Inc (DYAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013391
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dyadic International Inc (Dyadic) is a biotechnology company that discovers, develops, manufactures and commercializes protein-based drugs. The company utilizes its patented and proprietary technology Myceliopthora thermophila (C1) expression system, to conduct research and produce industrial enzymes. It also provides biologic vaccine and drug development services. Dyadic works in partnership with pharmaceutical company to develop imperative non-glycosylated therapeutic products such as insulin and ranibizumab with the help of C1 technology. The company caters to bioenergy, biopharmaceutical, biochemical and industrial enzyme industries. It operates through its laboratories and subsidiaries in the US and the Netherlands. Dyadic is headquartered in Jupiter, Florida, the US.

Dyadic International Inc (DYAI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dyadic International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Dyadic International Inc, Pharmaceuticals & Healthcare, Deal Details 9
Partnerships 9
Dyadic International Enters into R&D Agreement with BDI Holdings 9
Dyadic International Enters into Co-Development Agreement for C1 Technology 10
Licensing Agreements 11
BASF Enters Into Licensing Agreement With Dyadic International For C1 Technology 11
Dyadic International Inc – Key Competitors 12
Dyadic International Inc – Key Employees 13
Dyadic International Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Recent Developments 15
Financial Announcements 15
Nov 09, 2017: Dyadic International Reports Third Quarter 2017 Financial Results 15
Aug 10, 2017: Dyadic International Reports Second Quarter 2017 Financial Results 17
May 11, 2017: Dyadic International Reports First Quarter 2017 Financial Results 19
Mar 15, 2017: Dyadic International Reports 2016 Financial Results 21
Nov 10, 2016: Dyadic International Reports Third Quarter 2016 Financial Results 23
Aug 11, 2016: Dyadic International Reports Second Quarter 2016 Financial Results 25
May 12, 2016: Dyadic International Reports First Quarter 2016 Financial Results 27
Mar 29, 2016: Dyadic International Reports 2015 Annual Financial Results 29
Corporate Communications 31
Apr 06, 2017: Dyadic Announces Director Resignation 31
Aug 16, 2016: Dyadic International Appoints Arindam Bose, Ph.D., Distinguished Life Sciences Executive, to Board of Directors 32
Jan 19, 2016: Dyadic Announces Robert Burke Resignation 33
Legal and Regulatory 34
Apr 06, 2016: Dyadic International Announces it has Reached a Settlement with One of the Two Remaining Defendant Law Firms in its Professional Liability Litigation 34
Mar 03, 2016: Dyadic International Announces a January 6, 2017 Trial Date for Litigation Against Former Professional Services Providers 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Dyadic International Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dyadic International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Dyadic International Enters into R&D Agreement with BDI Holdings 9
Dyadic International Enters into Co-Development Agreement for C1 Technology 10
BASF Enters Into Licensing Agreement With Dyadic International For C1 Technology 11
Dyadic International Inc, Key Competitors 12
Dyadic International Inc, Key Employees 13
Dyadic International Inc, Subsidiaries 14

★海外企業調査レポート[Dyadic International Inc (DYAI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hostess Brands Inc (TWNK):企業の財務・戦略的SWOT分析
    Hostess Brands Inc (TWNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cheniere Energy Inc (LNG):石油・ガス:M&Aディール及び事業提携情報
    Summary Cheniere Energy Inc (Cheniere) is a midstream energy company that owns and operates LNG-related businesses. The company through its general partner, Cheniere Energy Partners, L.P. (Cheniere Partners) and Cheniere Energy Partners LP Holdings (Cheniere Holdings) owns and operates the Sabine Pa …
  • NTN Corp (6472):企業の財務・戦略的SWOT分析
    NTN Corp (6472) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Narodowy Bank Polski:企業の戦略的SWOT分析
    Narodowy Bank Polski - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …
  • Lloyds Banking Group Plc:企業の戦略・SWOT・財務情報
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Ark Restaurants Corp. (ARKR):企業の財務・戦略的SWOT分析
    Ark Restaurants Corp. (ARKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Changmao Biochemical Engineering Co., Ltd:企業の戦略・SWOT・財務情報
    Changmao Biochemical Engineering Co., Ltd - Strategy, SWOT and Corporate Finance Report Summary Changmao Biochemical Engineering Co., Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Zygo Corporation:企業の戦略的SWOT分析
    Zygo Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Concardis Gmbh:企業の戦略・SWOT・財務分析
    Concardis Gmbh - Strategy, SWOT and Corporate Finance Report Summary Concardis Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Scheid Vineyards Inc:企業の戦略・SWOT・財務情報
    Scheid Vineyards Inc - Strategy, SWOT and Corporate Finance Report Summary Scheid Vineyards Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Aeroflot Oao:企業の戦略・SWOT・財務分析
    Aeroflot Oao - Strategy, SWOT and Corporate Finance Report Summary Aeroflot Oao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Wistron Corporation:企業の戦略・SWOT・財務分析
    Wistron Corporation - Strategy, SWOT and Corporate Finance Report Summary Wistron Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Cyxone AB-製薬・医療分野:企業M&A・提携分析
    Summary Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company’s lead product include T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis …
  • Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報
    Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process include …
  • Evergreen Packaging Inc:企業の戦略・SWOT・財務情報
    Evergreen Packaging Inc - Strategy, SWOT and Corporate Finance Report Summary Evergreen Packaging Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Huttig Building Products Inc:企業の戦略・SWOT・財務情報
    Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report Summary Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Endologix Inc (ELGX):医療機器:M&Aディール及び事業提携情報
    Summary Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA p …
  • SNC-Lavalin Group Inc.:企業の戦略・SWOT・財務情報
    SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report Summary SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • FP Corporation:企業の戦略・SWOT・財務情報
    FP Corporation - Strategy, SWOT and Corporate Finance Report Summary FP Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆